tiprankstipranks
MATERNUS-Kliniken AG (DE:MAK)
XETRA:MAK
Want to see DE:MAK full AI Analyst Report?

MATERNUS-Kliniken AG (MAK) AI Stock Analysis

2 Followers

Top Page

DE:MAK

MATERNUS-Kliniken AG

(XETRA:MAK)

Select Model
Select Model
Select Model
Neutral 45 (OpenAI - 5.2)
Rating:45Neutral
Price Target:
€0.97
▼(-1.53% Downside)
Action:Reiterated
Date:07/07/26
The score is primarily constrained by weak financial performance—especially the very weak balance sheet (negative equity and high debt) and ongoing losses alongside a sharp 2025 revenue decline. Technical indicators are only mildly supportive due to short-term strength versus 20D/50D averages but lack longer-term trend confirmation. Valuation is also penalized because negative earnings (negative P/E) reflect continued unprofitability and there is no dividend yield data to offset risk.
Positive Factors
Recurring revenue model
MATERNUS’s core business is long‑term residential care where revenues come from recurring care reimbursements, resident co‑payments and accommodation charges. These predictable, contract‑like cash inflows support stable operating volumes and planning over multi‑month horizons.
Negative Factors
Very weak balance sheet
Negative equity and debt exceeding assets create a structurally impaired capital base. This elevates refinancing and covenant risk, limits borrowing capacity, and constrains strategic options; long‑term recovery will likely require significant deleveraging or fresh capital to restore financial flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring revenue model
MATERNUS’s core business is long‑term residential care where revenues come from recurring care reimbursements, resident co‑payments and accommodation charges. These predictable, contract‑like cash inflows support stable operating volumes and planning over multi‑month horizons.
Read all positive factors

MATERNUS-Kliniken AG (MAK) vs. iShares MSCI Germany ETF (EWG)

MATERNUS-Kliniken AG Business Overview & Revenue Model

Company Description
Maternus-Kliniken AG oversees a network of facilities that includes retirement and nursing residences, rehabilitation centers, and a variety of specialized service companies. This enterprise primarily focuses on delivering geriatric care and medic...
How the Company Makes Money
MATERNUS-Kliniken AG primarily generates revenue by providing long-term care services within its senior-care facilities. Key revenue streams typically include recurring payments for nursing and residential care (often comprising care-related reimb...

MATERNUS-Kliniken AG Financial Statement Overview

Summary
Overall financials are stressed. Income statement shows persistent losses and negative operating profitability, with a sharp ~33% revenue decline in 2025 despite some loss narrowing versus 2023. Balance sheet is the biggest weakness with consistently negative equity and high debt relative to assets, elevating refinancing risk. Cash flow is a relative bright spot with positive operating and improving free cash flow in 2025, but coverage of total debt remains modest.
Income Statement
22
Negative
Balance Sheet
9
Very Negative
Cash Flow
48
Neutral
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue118.00M114.00M102.31M106.70M111.44M
Gross Profit23.00M98.78M87.45M86.98M97.52M
EBITDA4.08M10.71M4.71M1.71M14.96M
Net Income-13.90M-13.16M-14.26M-14.08M-2.56M
Balance Sheet
Total Assets149.87M139.88M154.38M153.40M165.41M
Cash, Cash Equivalents and Short-Term Investments5.35M4.94M9.99M5.20M16.02M
Total Debt183.19M165.41M112.35M117.81M123.65M
Total Liabilities230.46M206.72M206.49M190.95M186.76M
Stockholders Equity-80.59M-66.84M-53.76M-39.30M-25.34M
Cash Flow
Free Cash Flow11.16M13.86M-1.44M2.33M15.32M
Operating Cash Flow14.03M15.07M2.52M4.33M17.24M
Investing Cash Flow-2.87M-1.07M-3.96M-2.00M-1.92M
Financing Cash Flow-10.17M-11.68M-69.00K-12.76M-12.79M

MATERNUS-Kliniken AG Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.98
Price Trends
50DMA
0.96
Positive
100DMA
1.04
Negative
200DMA
1.04
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
52.77
Neutral
STOCH
38.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:MAK, the sentiment is Positive. The current price of 0.98 is above the 20-day moving average (MA) of 0.93, above the 50-day MA of 0.96, and below the 200-day MA of 1.04, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.77 is Neutral, neither overbought nor oversold. The STOCH value of 38.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:MAK.

MATERNUS-Kliniken AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
€162.00M27.9924.05%33.49%81.79%
63
Neutral
€191.90M6.7611.90%1.12%5.13%11.89%
57
Neutral
€903.67M22.503.04%0.77%6.06%0.93%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
45
Neutral
€20.34M-1.2821.40%3.53%-5.29%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:MAK
MATERNUS-Kliniken AG
0.97
-0.11
-10.19%
DE:MED
MEDICLIN
4.04
1.17
40.82%
DE:RHK
RHON-KLINIKUM AG
13.50
1.59
13.39%
DE:LIK
Limes Schlosskliniken AG
540.00
188.82
53.77%
DE:EIF
Eifelhoehen-Klinik AG
4.18
2.69
180.54%
DE:JTH0
Gesundheitswelt Chiemgau AG
10.00
-2.08
-17.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 07, 2026